Outcome of People with Parkinson’s Disease Treated with Levodopa-Entacapone-Carbidopa Intestinal Gel Who Failed Previous Subcutaneous Foslevodopa/Foscarbidopa

<b>Introduction:</b> The clinical outcome of switching to levodopa-entacapone-carbidopa intestinal gel (LECIG) after failure of subcutaneous foslevodopa/foscarbidopa (fLD/fCD) is unknown. We analyze it in people with Parkinson’s disease (PwP) treated in Spain. <b>Methods:</b> Retrospective analysis...

Descrición completa

Detalles Bibliográficos

Principais autores:	Diego Santos García, Inés Legarda, Tamara M. González Fernández, Ana Rodríguez Sanz, Maria Isabel Morales-Casado, Alejandro Peral, Nuria Caballol, María Álvarez Sauco, Iria Campos Rodríguez, Déborah Alonso Modino, Lydia López Manzanares, Jesús Olivares Romero, Alberto Blanco Ollero
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2026-03-01
Series:	Brain Sciences
Assuntos:	effectiveness foslevodopa/foscarbidopa levodopa-entacapone-carbidopa Parkinson’s disease safety
Acceso en liña:	https://www.mdpi.com/2076-3425/16/3/343
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!